SMAD4 Antibody

Biorbyt

SMAD4 Antibody

16

Optimal dilution of the antibody should be determined by the researcher.

ELISA

ELISA (order BSA-free format for coating) ELISA

Research Use Only

Monoclonal

SMAD4/2524

Unconjugated

SMAD4

SMAD family member 4

DPC4, JIP, MADH4, MYHRS, mothers against decapentaplegic homolog 4, MAD homolog 4, SMAD, mothers against DPP homolog 4, deleted in pancreatic carcinoma locus 4, deletion target in pancreatic carcinoma 4, mothers against decapentaplegic, Drosophila, homolog of, 4

Mouse

IgG2a

Mothers against decapentaplegic homolog 4

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80% of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

Human

-20°C,2°C to 8°C

12352203